Leo International Precision Health is building Europe’s first integrated AI-driven healthcare ecosystem. Through the acquisition and reconfiguration of attractive AI-driven precision healthcare assets, the company creates a scalable synergy engine that combines technology, data, and operations to accelerate and improve clinical impact and portfolio performance. The company generates shareholder value through asset reconfiguration, revenue growth, licensing and royalties, as well as selectively spinning off asset companies.
As of Dec 16, 2025, the portfolio comprises six asset companies:
| Asset | Shareholding [%] |
| amiko AI | 51% |
| Danner Laboratory, Inc. | 51% |
| Dr. PAIN | 100% |
| UHO Wellness Corporation | 67% |
| Pathomics Health Pte. Ltd. | 51% |
| Renhe Biotech Pty. Ltd. | 51% |
| Valuation of contribution in kind | EUR 109.6 M |
The ticker symbol on the Frankfurt stock exchange is LEOW.
As of Dec 31, 2025, there are 550,000 shares issued.
The company's dividend policy for the financial year 2025 shall be to retain all earnings within the business to fund strategic growth initiatives. No dividends will be declared or paid to shareholders during this period, as reinvestment of profits is deemed the optimal strategy for enhancing long-term shareholder value and maximizing capital appreciation.
SPOBAG AG used to be a listed shell company. With the completion of the reverse-IPO via a mandatory takeover process completed in June 2025, SPOBAG AG became Leo International Precision Health AG with its new business purpose.